Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. A phase I/II study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results